Methylcobalamin vs cyanocobalamin SEO Brief & AI Prompts

Methylcobalamin vs Cyanocobalamin vs Adenosylcobalamin: choice depends on clinical context—methylcobalamin and adenosylcobalamin are the two active intracellular coenzyme forms required for methylation and for methylmalonyl‑CoA mutase, while cyanocobalamin is a synthetic, stable precursor that must be converted in vivo and is widely used in oral and intramuscular B12 supplementation (common intramuscular replacement dose 1,000 µg). Serum vitamin B12 below ~200 pg/mL (≈148 pmol/L) suggests deficiency, and biochemical confirmation commonly uses serum methylmalonic acid (MMA), with values above ~0.4 µmol/L supporting deficiency. Choice is guided by biochemical testing and factors such as renal function, smoking status and neuropathy. Hydroxocobalamin is a longer‑acting injectable alternative preferred in some regions.

Biochemically, methylcobalamin serves as the methyl donor cofactor for methionine synthase in the cytosol while adenosylcobalamin is the mitochondrial cofactor for methylmalonyl‑CoA mutase; cyanocobalamin must undergo decyanation and enzymatic conversion to those active forms. Clinical assays such as holotranscobalamin and serum methylmalonic acid are used to assess tissue B12 status, and LC‑MS/MS can distinguish circulating cobalamin forms for research. B12 absorption is typically intrinsic factor–mediated in the terminal ileum, but high‑dose oral B12 achieves clinical repletion by passive diffusion at an estimated ~1% efficiency. In the supplements context, methylcobalamin is marketed for methylation support while cyanocobalamin is used for stable, inexpensive B12 supplementation. The Schilling test is historically referenced but is rarely used clinically now.

The key nuance is that cobalamin forms are not universally interchangeable in all clinical contexts. For routine replacement in patients with dietary insufficiency or post‑gastric surgery, cyanocobalamin or hydroxocobalamin injected at 1,000 µg achieves repletion, but clinicians should avoid blanket superiority claims for methylcobalamin or adenosylcobalamin because randomized head‑to‑head trials with clinical endpoints are limited. In patients with renal failure or heavy smoking, the cyanide moiety of cyanocobalamin can be clinically relevant because decyanation produces small amounts of cyanide that are renally cleared; many nephrology protocols favor hydroxocobalamin or methylcobalamin. For peripheral neuropathy some trials used methylcobalamin 500–1,500 µg/day with symptomatic benefit reported, but evidence quality varies and B12 injections versus high‑dose oral strategies differ by absorption status. Tissue retention and CSF penetration differ between forms.

Practical application is to match form to patient needs: to correct deficiency in patients with intact absorption, oral cyanocobalamin or oral high‑dose therapy is cost‑effective; for malabsorption or pernicious anemia, parenteral hydroxocobalamin or cyanocobalamin 1,000 µg intramuscularly is standard; for renal impairment, smokers, or some neuropathic presentations, clinicians often prefer hydroxocobalamin or methylcobalamin. Monitoring should use serum B12 with reflex methylmalonic acid or holotranscobalamin where available, and dosing should be adjusted to response and retention. Follow‑up testing at 4–12 weeks confirms biochemical response. This page contains a structured, step-by-step framework for diagnostic testing and treatment selection.